Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Friday's Bonus Story Got 1K to Invest? These 3 Stocks Are Still Attractive BuysWritten by Chris Markoch. Published 10/21/2025. 
Key Points - These three companies combine strong fundamentals with durable growth trends that can reward patient investors.
- Each stock offers exposure to major market themes without the excessive volatility of speculative trades.
- Analysts expect continued profit growth, suggesting there’s still room for these stocks to run.
The stock market is giving off 2021 vibes. Many investors are swinging for the fences on stocks they can buy for $10 or less per share. But if you have $1,000 to put into the market, there are several quality names that offer significant upside even though—in some cases—they've already outperformed the market in 2025. If you’re focused on long-term growth, these opportunities can generate a solid return without the volatility that often comes with low-priced stocks. Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX). But the real opportunity is now – before they hit the big stage.
Their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results. Their products are already available through e-commerce giants like Walmart, Amazon, and Kroger, and they plan to expand internationally. Become a Med-X Shareholder Before Their Nasdaq Plans Unfold Beyond their individual market niches, there’s a fundamental reason to consider these picks: analysts are projecting each to post earnings per share (EPS) growth of over 20% in the next 12 months. Earnings growth is the primary driver of stock-price appreciation, so there's still room for these three stocks to run. AMD Stock: Riding the AI Infrastructure Wave Advanced Micro Devices (NASDAQ: AMD) has been part of the catch-up trade in the chip sector. This isn’t about taking market share from NVIDIA Corp. (NASDAQ: NVDA); it’s about meeting the insatiable demand for artificial intelligence (AI) infrastructure. Businesses are seeking alternatives to NVIDIA out of necessity, not because NVIDIA’s GPUs are deficient. They still want vendors on the cutting edge of GPU design, and AMD fits that description—evidenced by commitments from OpenAI and Oracle. AMD stock is up more than 92% in 2025, which may lead some investors to wonder whether there’s still room to chase the name, especially since it’s trading slightly above the analyst consensus price target. Analysts are forecasting over 36% earnings growth for AMD in the next 12 months, which helps justify a forward price-to-earnings (P/E) ratio near 60x in today’s richly valued tech sector. Consensus price targets are also shifting higher. In the 30 days ending Oct. 20, several analysts raised their targets. On Oct. 20, Bank of America lifted its target from $250 to $300 (a 27% increase), while HSBC boosted its target to $310 from $185—an increase of more than 42%. Uber Stock: Profitable, Undervalued, and Expanding Uber Technologies Inc. (NYSE: UBER) is an example of patient investors being rewarded. The company already controls more than 70% of the ride-sharing market, which remains its core business, and Uber Eats—once a pandemic necessity—has become a key revenue stream. Uber is also positioning itself for the future of transportation through partnerships and investments in areas such as autonomous vehicles and electric vertical take-off and landing vehicles (eVTOLs). These moves have helped Uber become consistently profitable and generate strong free cash flow. As the company pays down debt, it is increasingly likely to return capital to shareholders via buybacks and, potentially, dividends. UBER stock presents an attractive setup: analysts project earnings growth of more than 37% over the next 12 months. That projected growth outpaces what the stock’s current forward P/E of roughly 36x implies, suggesting the shares may be undervalued—a view that is beginning to show up in analysts’ price targets. LLY Stock: A Blue-Chip Buy-the-Dip Opportunity Eli Lilly & Co. (NYSE: LLY) is the current leader in the GLP-1 market. Analysts project the company could capture more than 50% of the obesity-drug market by 2026. Eli Lilly is also testing new indications—such as sleep apnea and heart failure—that would expand the addressable market for its drugs. There are additional reasons to be bullish on LLY stock. The company had its Alzheimer’s drug Donanemab approved by the FDA in 2025, which has shown an ability to slow cognitive decline in early Alzheimer’s patients. Lilly also has a deep pipeline that includes oncology and cardiometabolic programs. LLY stock is up just 4% this year amid uncertainty around the GLP-1 market. Still, analysts forecast about 32% earnings growth over the next 12 months, roughly in line with the company’s forward P/E of around 34x. Analysts' consensus price targets imply roughly 19% upside from the current price, indicating additional potential appreciation if those expectations hold.
|
Post a Comment
Post a Comment